Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer

Exclusion Criteria

• •uncontrolled diabetes mellitus, defined as fasting serum glucose \> 1.5 times ULN
• •severely impaired lung function
• •known HV infection
• •active, bleeding diathesis
• •unstable angina pectoris, symptomatic congestive heart failure, or myocardial infarction within the past 6 months
• •serious uncontrolled cardiac arrhythmia
• •active or uncontrolled infection requiring parenteral antimicrobials
• •known liver disease (e.g., cirrhosis, chronic active hepatitis, or chronic persistent hepatitis)
• •inability to swallow, impaired gastrointestinal (GI) function, or GI disease (e.g., ulcerative colitis, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) that would significantly alter the absorption of study drugs or preclude the use of oral medications
• •other malignancy within the past 5 years except for nonmelanoma skin cancer or cervical carcinoma in situ
• •known hypersensitivity to everolimus, sirolimus, or temsirolimus or to their excipients
• •other medical conditions that, in the opinion of the investigator, would preclude study participation
• •prior mTOR inhibitors (e.g., rapamycin, CCI-779)
• •concurrent chronic treatment with steroids or another immunosuppressive agent
• •concurrent prophylactic use of hematopoietic growth factors
• •concurrent anticancer agents or therapy (including radiotherapy)
• •other concurrent experimental agents
• •concurrent strong inhibitors or inducers of the isoenzyme CYP3A4